Intra-individual Dose Escalation of Abiraterone Acetate According to Its Plasma Concentration in Patients With Progressive Castration-resistant Metastatic Prostate Cancer

Trial Profile

Intra-individual Dose Escalation of Abiraterone Acetate According to Its Plasma Concentration in Patients With Progressive Castration-resistant Metastatic Prostate Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Abiraterone acetate (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms OPTIMABI
  • Most Recent Events

    • 03 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.
    • 01 Mar 2018 Status changed from recruiting to not yet recruiting.
    • 15 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top